ASH 2022 | The efficacy of selinexor, carfilzomib & dexamethasone in triple-class refractory multiple myeloma
Gary Schiller, MD, University of California, Los Angeles, Los Angeles, CA, outlines results from a study investigating the efficacy of selinexor in combination with carfilzomib and dexamethasone in patients with triple-class treated and refractory multiple myeloma (MM). Results demonstrated a high response rate of 66%, a median duration of remission (DOR) of 12 months and a progression-free survival (PFS) of 13.8 months. The combinational therapy was also well tolerated. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Constellation: Research Funding; Sellas: Research Funding; Samus: Research Funding; Sangamo: Research Funding; Amgen: Current equity holder in publicly-traded company, Honoraria; Medimmune: Research Funding; FujiFilm: Research Funding; Millennium: Research Funding; Daiichi-Sankyo: Research Funding; Stemline: Research Funding; Deciphera: Research Funding; Genentech-Roche: Research Funding; Gilead: Research Funding; Karyopharm: Research Funding, Speakers Bureau; Incyte: Other: speaker fees, Research Funding, Speakers Bureau; Deltafly: Research Funding; CTI: Research Funding; Ono Pharma: Honoraria; Arog: Research Funding; Forma: Research Funding; Novartis: Honoraria, Other: Speaker fees, Research Funding; Johnson & Johnson: Current equity holder in publicly-traded company; AVM Biopharma: Research Funding; Cellectis: Research Funding; Trovagen: Research Funding; Glycomimetics: Research Funding; Pfizer: Research Funding; AstraZeneca: Honoraria; Kite, a Gilead Company: Research Funding, Speakers Bureau; Cyclacel: Research Funding; AltruBio: Research Funding; Celgene: Consultancy, Research Funding, Speakers Bureau; Janssen: Research Funding; Stemline: Speakers Bureau; Mateon: Research Funding; Geron: Research Funding; Cellerant: Research Funding; Regimmune: Research Funding; PreCOG LLC: Research Funding; Actuate: Research Funding; Jazz: Consultancy; Onconova: Research Funding; Gamida: Research Funding; Takeda: Research Funding; Tolero: Research Funding; Bristol Myers Squibb: Current equity holder in publicly-traded company, Speakers Bureau; Astellas: Research Funding, Speakers Bureau; Agios: Consultancy, Honoraria; Actinium: Research Funding; AbbVie: Research Funding, Speakers Bureau.
